Abstract
Biomedicine has made incredible progress during the last decade offering totally new possibilities to treat various types of diseases, in particular cancer. Clinically relevant genomic analyses today are feasible within days and will be possible within hours in some years. While the costs of molecular diagnostics are decreasing the treatment procedures will remain extremely costly for years. Since the number of molecular-based intervention will increase dramatically the overall burden of the health care system will become a substantial challenge. All partners involved therein have to recognize the facts, discuss the challenges and find solutions by tearing down existing boundaries, otherwise a strain on or even a collapse of the system cannot be excluded. The reproach ‘Only the rich survive’ has to be avoided to ensure the balance and harmony of the social system.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Camidge DR, Bang YJ, Kwak EL et al (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13:1011–1019
Dietel M, Jöhrens K, Laffert M et al (2013) Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther 20(4):211–221
Dubsky P, Brase JC, Austrian Breast and Colorectal Cancer Study Group (ABCSG) et al (2013) The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2-breast cancer patients. Br J Cancer 109:2959–2964
Flaherty KT, Infante JR, Daud A (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694–1703
Kim DW et al (2012) Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). Presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, 1–5 June 2012; Abstract 7533. http://meetinglibrary.asco.org/content/75135?media=vm&poster=1. Accessed 14 June 2015
Queirolo P, Picasso V, Spagnolo F (2015) Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. Cancer Treat Rev 41(6):519–26. doi:10.1016/j.ctrv.2015.04.010 [Epub ahead of print]
World Health Organization (2015) World Health Statistics 2015. http://www.who.int/gho/publications/world_health_statistics/2015/en/. Accessed 6 June 2015
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Dietel, M. (2016). Personalized Medicine Challenges the Health Care System. In: Albach, H., Meffert, H., Pinkwart, A., Reichwald, R., von Eiff, W. (eds) Boundaryless Hospital. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-49012-9_8
Download citation
DOI: https://doi.org/10.1007/978-3-662-49012-9_8
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-49010-5
Online ISBN: 978-3-662-49012-9
eBook Packages: Business and ManagementBusiness and Management (R0)